CA3007050C - Pharmaceutical composition comprising a formoterol compound - Google Patents
Pharmaceutical composition comprising a formoterol compound Download PDFInfo
- Publication number
- CA3007050C CA3007050C CA3007050A CA3007050A CA3007050C CA 3007050 C CA3007050 C CA 3007050C CA 3007050 A CA3007050 A CA 3007050A CA 3007050 A CA3007050 A CA 3007050A CA 3007050 C CA3007050 C CA 3007050C
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- formoterol
- component
- weight
- impurities
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1521456.2A GB201521456D0 (en) | 2015-12-04 | 2015-12-04 | Pharmaceutical composition |
| GB1521456.2 | 2015-12-04 | ||
| GB1615916.2A GB2554092A (en) | 2016-09-19 | 2016-09-19 | Pharmaceutical composition |
| GB1615916.2 | 2016-09-19 | ||
| PCT/GB2016/053812 WO2017093758A1 (en) | 2015-12-04 | 2016-12-02 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3007050A1 CA3007050A1 (en) | 2017-06-08 |
| CA3007050C true CA3007050C (en) | 2020-12-08 |
Family
ID=57750288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3007050A Active CA3007050C (en) | 2015-12-04 | 2016-12-02 | Pharmaceutical composition comprising a formoterol compound |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11559505B2 (https=) |
| EP (4) | EP3556348B1 (https=) |
| JP (3) | JP6899824B2 (https=) |
| CN (2) | CN112472689B (https=) |
| AU (3) | AU2016364650B2 (https=) |
| BR (2) | BR112018011266B1 (https=) |
| CA (1) | CA3007050C (https=) |
| ES (4) | ES3060273T3 (https=) |
| MX (1) | MX375783B (https=) |
| WO (1) | WO2017093758A1 (https=) |
| ZA (1) | ZA201803678B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| EP3556348B1 (en) | 2015-12-04 | 2021-02-03 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition |
| EP3515451B2 (en) * | 2016-09-19 | 2023-10-04 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition |
| ES2904823T3 (es) * | 2016-09-19 | 2022-04-06 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende bromuro de tiotropio |
| MX387723B (es) | 2016-09-19 | 2025-03-18 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende bromuro de glicopirronio, propionato de fluticasona y 1,1-difluoroetano. |
| MX384545B (es) | 2016-09-19 | 2025-03-14 | Mexichem Fluor Sa De Cv | Composicion farmaceutica |
| US11260052B2 (en) | 2016-09-19 | 2022-03-01 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| CN109771398B (zh) * | 2019-02-25 | 2019-09-20 | 广州南鑫药业有限公司 | 一种帕拉米韦溶液型吸入剂及其制备方法 |
| GB2584686A (en) * | 2019-06-11 | 2020-12-16 | Mexichem Fluor Sa De Cv | Methods |
| CN110840864B (zh) * | 2019-12-20 | 2022-02-22 | 广州健康元呼吸药物工程技术有限公司 | 一种β2受体激动剂吸入气雾剂及包含该吸入气雾剂的产品 |
| WO2021151857A1 (en) * | 2020-01-28 | 2021-08-05 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
| GB202001537D0 (en) | 2020-02-05 | 2020-03-18 | Consort Medical Plc | Pressurised dispensing container |
| GEAP202416041A (en) * | 2020-02-20 | 2024-03-25 | Chiesi Farm Spa | Pressurised metered dose inhalers comprising buffered pharmaceutical formulation |
| CN116338014A (zh) * | 2021-12-23 | 2023-06-27 | 上海医药工业研究院有限公司 | 一种吸入用药物组合物的组分分离检测方法 |
| FR3137830A1 (fr) * | 2022-07-13 | 2024-01-19 | Aptar France Sas | Composition pharmaceutique comprenant du salbutamol |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| US5439670A (en) * | 1989-11-28 | 1995-08-08 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| IL97065A (en) | 1990-02-02 | 1994-01-25 | Fisons Plc | Repellent preparations for aerosol |
| DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
| MX9203481A (es) | 1990-10-18 | 1992-07-01 | Minnesota Mining & Mfg | Formulaciones. |
| US6123924A (en) | 1991-09-25 | 2000-09-26 | Fisons Plc | Pressurized aerosol inhalation compositions |
| US7105152B1 (en) | 1991-12-18 | 2006-09-12 | 3M Innovative Properties Company | Suspension aerosol formulations |
| ES2172510T3 (es) | 1991-12-18 | 2002-10-01 | Astrazeneca Ab | Nueva combinacion de formoterol y budesonida. |
| EP0806940B1 (en) | 1994-12-22 | 2003-04-09 | AstraZeneca AB | Aerosol drug formulations |
| MX9707862A (es) | 1995-04-14 | 1997-11-29 | Glaxo Wellcome Inc | Inhalador de dosis medida para el propionato de fluticasona. |
| AU718967B2 (en) | 1997-02-05 | 2000-05-04 | Jagotec Ag | Medical aerosol formulations |
| SE9703407D0 (sv) * | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| CN1169520C (zh) | 1997-09-29 | 2004-10-06 | 耐科塔医药公司 | 多孔微粒及其使用方法 |
| US6309623B1 (en) * | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| US6103266A (en) | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
| US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
| CN1150890C (zh) | 1998-08-04 | 2004-05-26 | 杰格研究股份公司 | 药用气溶胶制剂 |
| GB9904919D0 (en) | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
| GB2392915B (en) | 1999-09-11 | 2004-04-28 | Glaxo Group Ltd | Pharmaceutical formulation of fluticasone propionate |
| US6432415B1 (en) | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
| JP5392880B2 (ja) | 2000-05-22 | 2014-01-22 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 加圧式定量吸入器のための安定な製薬学的溶液製剤 |
| US20060257324A1 (en) | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| CN1144582C (zh) | 2000-11-28 | 2004-04-07 | 中国药科大学 | 治疗呼吸系统疾病的无氟里昂药用气雾剂 |
| TWI324934B (en) | 2001-08-28 | 2010-05-21 | Schering Corp | Pharmaceutical compositions for the treatment of asthma |
| SE0200312D0 (sv) | 2002-02-01 | 2002-02-01 | Astrazeneca Ab | Novel composition |
| GB0207906D0 (en) | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| WO2004015822A1 (ja) | 2002-08-08 | 2004-02-19 | Fujikura Ltd. | 電気コネクタおよびケ−ブル |
| GB0323685D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB0323684D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| WO2006004646A1 (en) | 2004-06-28 | 2006-01-12 | Nektar Therapeutics | Aerosol formulation comprising nicotine salt |
| ES2259915B1 (es) | 2005-03-15 | 2007-12-16 | Laboratorio Aldo-Union, S.A. | Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion. |
| WO2007020204A2 (en) | 2005-08-12 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate |
| DE102006017320A1 (de) | 2006-04-11 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel |
| EP2444080A3 (en) | 2007-02-09 | 2012-05-02 | Schering Corporation | Stable Pharmaceutical Drug Aerosols |
| US8597616B2 (en) * | 2007-10-22 | 2013-12-03 | Board Of Regents Of The University Of Texas System | Dry powder drug delivery formulations, methods of use, and devices therefore |
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| GB0915106D0 (en) | 2009-08-28 | 2009-10-07 | Glaxo Group Ltd | Process |
| RS53514B1 (sr) | 2009-10-02 | 2015-02-27 | Chiesi Farmaceutici S.P.A. | Farmaceutske aerosolne formulacije od formoterola i beklometazon dipropionata |
| WO2011076842A2 (en) | 2009-12-23 | 2011-06-30 | Chiesi Farmaceutici S.P.A. | Aerosol formulation for copd |
| RU2568882C2 (ru) * | 2010-07-16 | 2015-11-20 | Сипла Лимитед | Фармацевтические композиции |
| EP2749283A3 (en) * | 2011-02-17 | 2014-08-20 | Cipla Limited | Combination of glycopyrronium and olodaterol |
| GB201108039D0 (en) | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
| GB201117619D0 (en) * | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
| GB201117621D0 (en) * | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
| CN102362860A (zh) * | 2011-10-27 | 2012-02-29 | 江阴长风医药科技有限公司 | 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂 |
| WO2014016548A2 (en) | 2012-07-27 | 2014-01-30 | Cipla Limited | Pharmaceutical composition |
| WO2014064410A2 (en) | 2012-10-23 | 2014-05-01 | Cipla Limited | Pharmaceutical composition |
| GB201306984D0 (en) | 2013-04-17 | 2013-05-29 | Mexichem Amanco Holding Sa | Composition |
| EP3384898A1 (en) | 2013-12-30 | 2018-10-10 | Chiesi Farmaceutici S.p.A. | Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination |
| EP3556348B1 (en) | 2015-12-04 | 2021-02-03 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition |
| MX384545B (es) | 2016-09-19 | 2025-03-14 | Mexichem Fluor Sa De Cv | Composicion farmaceutica |
-
2016
- 2016-12-02 EP EP19178843.9A patent/EP3556348B1/en active Active
- 2016-12-02 ES ES20169450T patent/ES3060273T3/es active Active
- 2016-12-02 JP JP2018528946A patent/JP6899824B2/ja active Active
- 2016-12-02 ES ES19178843T patent/ES2866175T3/es active Active
- 2016-12-02 EP EP16822716.3A patent/EP3383366B2/en active Active
- 2016-12-02 BR BR112018011266-6A patent/BR112018011266B1/pt active IP Right Grant
- 2016-12-02 BR BR122020022602-1A patent/BR122020022602B1/pt active IP Right Grant
- 2016-12-02 US US15/781,045 patent/US11559505B2/en active Active
- 2016-12-02 ES ES16822716T patent/ES2796177T5/es active Active
- 2016-12-02 CN CN202011316904.7A patent/CN112472689B/zh active Active
- 2016-12-02 CA CA3007050A patent/CA3007050C/en active Active
- 2016-12-02 CN CN201680071126.5A patent/CN108289843B/zh active Active
- 2016-12-02 MX MX2018006800A patent/MX375783B/es active IP Right Grant
- 2016-12-02 AU AU2016364650A patent/AU2016364650B2/en active Active
- 2016-12-02 WO PCT/GB2016/053812 patent/WO2017093758A1/en not_active Ceased
- 2016-12-02 EP EP20169450.2A patent/EP3701940B1/en active Active
- 2016-12-02 ES ES19178832T patent/ES2869176T3/es active Active
- 2016-12-02 EP EP19178832.2A patent/EP3556347B1/en active Active
-
2018
- 2018-06-01 ZA ZA2018/03678A patent/ZA201803678B/en unknown
-
2019
- 2019-04-24 AU AU2019202875A patent/AU2019202875B2/en active Active
- 2019-04-24 AU AU2019202874A patent/AU2019202874C1/en active Active
- 2019-09-18 US US16/575,168 patent/US11559507B2/en active Active
- 2019-09-18 US US16/575,069 patent/US11559506B2/en active Active
- 2019-12-23 JP JP2019232073A patent/JP6931383B2/ja active Active
- 2019-12-23 JP JP2019232074A patent/JP6899889B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019202874B2 (en) | Pharmaceutical composition | |
| AU2019201520C1 (en) | Pharmaceutical composition | |
| CA3037080C (en) | Stable pharmaceutical compositions comprising indacaterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis) | |
| CA3036628C (en) | Pharmaceutical compositions comprising tiotropium bromide monohydrate and 1,1-difluoroethane | |
| GB2554092A (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180531 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241128 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241128 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241128 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251120 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251120 |